Abstract
The present study was conducted to evaluate activity and toxicity of the FLEC (folinic acid 100 mg/m2; 5-fluorouracil 1000 mg/m2; carboplatin 300 mg/m2; epirubicin 60 mg/m2) schedule as second-line treatment for progressive locally advanced or metastatic pancreatic cancer (LAMPC). FLEC was administered every 3 weeks with an angiographic catheter introduced into the tumor vascular bed. Thirty-two patients were enrolled. Twenty patients had a PS of 2. Twenty-five patients had metastatic disease to liver. Seven (21.9%) partial responses were observed (WHO criteria). Fifteen patients (46.9%) had stable disease and ten patients (31.2%) had progressive disease. The median OS from the diagnosis was 11.8 months. PS (p=0.0308) and pain (WHO scale, p=0.0222; analogic scale, p=0.0446) significantly improved after therapy. No patient discontinued treatment because of toxicity (NCI-CTC criteria). The current study shows that intraarterial chemotherapy is a good therapeutic option in second-line treatment of LAMPC.
| Original language | English |
|---|---|
| Pages (from-to) | 782-787 |
| Number of pages | 6 |
| Journal | Frontiers in Bioscience |
| Volume | 11 |
| Issue number | 1 P.447-888 |
| Publication status | Published - 2006 |
Fingerprint
Keywords
- Intraarterial Chemotherapy
- Pancreatic Adenocarcinoma
- Second-Line Chemotherapy
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Biochemistry
- Cell Biology
Cite this
Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma. / Barletta, Emiddio; Fiore, Francesco; Daniele, Bruno; Ottaiano, Alessandro; D'Angelo, Roberto; Ferrari, Ettore; Formato, Roberta; Tortoriello, Anna; Turitto, Giacinto; Bruni, Giovanni Salvatore; Pignata, Sandro; Iaffaioli, Rosario Vincenzo.
In: Frontiers in Bioscience, Vol. 11, No. 1 P.447-888, 2006, p. 782-787.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma
AU - Barletta, Emiddio
AU - Fiore, Francesco
AU - Daniele, Bruno
AU - Ottaiano, Alessandro
AU - D'Angelo, Roberto
AU - Ferrari, Ettore
AU - Formato, Roberta
AU - Tortoriello, Anna
AU - Turitto, Giacinto
AU - Bruni, Giovanni Salvatore
AU - Pignata, Sandro
AU - Iaffaioli, Rosario Vincenzo
PY - 2006
Y1 - 2006
N2 - The present study was conducted to evaluate activity and toxicity of the FLEC (folinic acid 100 mg/m2; 5-fluorouracil 1000 mg/m2; carboplatin 300 mg/m2; epirubicin 60 mg/m2) schedule as second-line treatment for progressive locally advanced or metastatic pancreatic cancer (LAMPC). FLEC was administered every 3 weeks with an angiographic catheter introduced into the tumor vascular bed. Thirty-two patients were enrolled. Twenty patients had a PS of 2. Twenty-five patients had metastatic disease to liver. Seven (21.9%) partial responses were observed (WHO criteria). Fifteen patients (46.9%) had stable disease and ten patients (31.2%) had progressive disease. The median OS from the diagnosis was 11.8 months. PS (p=0.0308) and pain (WHO scale, p=0.0222; analogic scale, p=0.0446) significantly improved after therapy. No patient discontinued treatment because of toxicity (NCI-CTC criteria). The current study shows that intraarterial chemotherapy is a good therapeutic option in second-line treatment of LAMPC.
AB - The present study was conducted to evaluate activity and toxicity of the FLEC (folinic acid 100 mg/m2; 5-fluorouracil 1000 mg/m2; carboplatin 300 mg/m2; epirubicin 60 mg/m2) schedule as second-line treatment for progressive locally advanced or metastatic pancreatic cancer (LAMPC). FLEC was administered every 3 weeks with an angiographic catheter introduced into the tumor vascular bed. Thirty-two patients were enrolled. Twenty patients had a PS of 2. Twenty-five patients had metastatic disease to liver. Seven (21.9%) partial responses were observed (WHO criteria). Fifteen patients (46.9%) had stable disease and ten patients (31.2%) had progressive disease. The median OS from the diagnosis was 11.8 months. PS (p=0.0308) and pain (WHO scale, p=0.0222; analogic scale, p=0.0446) significantly improved after therapy. No patient discontinued treatment because of toxicity (NCI-CTC criteria). The current study shows that intraarterial chemotherapy is a good therapeutic option in second-line treatment of LAMPC.
KW - Intraarterial Chemotherapy
KW - Pancreatic Adenocarcinoma
KW - Second-Line Chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=32944476913&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=32944476913&partnerID=8YFLogxK
M3 - Article
C2 - 16146770
AN - SCOPUS:32944476913
VL - 11
SP - 782
EP - 787
JO - Frontiers in Bioscience - Landmark
JF - Frontiers in Bioscience - Landmark
SN - 1093-9946
IS - 1 P.447-888
ER -